|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 96.92 USD | -0.92% |
|
+1.43% | -1.87% |
| 17/04 | Goldman Sachs Adjusts Incyte Price Target to $100 From $98, Maintains Neutral Rating | MT |
| 14/04 | Pharma sector doubles down on AI amid hopes of slashing costs, timelines | RE |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bullish | Neutral | Bullish |
| Resistance | 97.82 | 110.57 | 108.39 |
| Spread/Res. | -0.92% | -12.35% | -10.58% |
| Spread/Supp. | +3.45% | +12.48% | +11.59% |
| Support | 93.69 | 86.17 | 86.85 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Equities
- INCY Stock
- Charts Incyte Corporation
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition